611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Toxins in Home Furnishings Can Be Passed on to KidsKratom-Related Poisonings Are Soaring, Study FindsFDA Aims to Strengthen Sunscreen RulesBrain Condition CTE Seen in H.S. Football Players: StudyPregnant Women Should Delay Gallbladder Surgery, Study FindsGut Microbes May Help Drive Lupus, Study FindsMost Hip, Knee Replacements Last Decades, Study FindsAHA News: Living Near Convenience Stores Could Raise Risk of Artery-Clogging ConditionPossible Parkinson's 'Pandemic' Looms: Report'Apple-Shaped' Body? 'Pear-Shaped'? Your Genes May TellProtect Your Aging Eyes From Macular DegenerationKidney Failure Patients Face Higher Risk of Cancer DeathHow Inactivity and Junk Food Can Harm Your BrainTattooed and Need an MRI Scan? What You Need to KnowGot the Flu? You Probably Shouldn't Head to the ERStudy Reaffirms Safety of Hepatitis C Meds in Liver Cancer PatientsSmart Steps for Healthy FeetOpioids Overprescribed for Common Children's Fracture, Study SaysNew Hepatitis Meds Are Saving Lives: StudyGun Injuries Bring Especially Tough RecoveriesAspirin Can Help Prevent Colon Cancer, But Many at Risk Don't Take ItAre Scientists Closer to Growing Made-to-Order Kidneys?Worldwide, More Die After Surgery Than From HIV, Malaria: StudyBlood Thinning Drug May Be Safer Option Against Recurrent StrokeStudy Ties Cancer-Causing HPV to Heart Disease, TooDangerous Bacteria May Lurk in Hospital SinksAs U.S. Measles Outbreaks Spread, Why Does 'Anti-Vax' Movement Persist?Cablivi Approved for Rare Clotting DisorderNew Antibiotic Treats Pneumonia, Skin InfectionsOpioid OD Deaths Are Saving Lives Through TransplantationHealth Tip: Know Your Family's Medical HistoryAHA News: High Blood Pressure Top Risk Factor for Stroke in Young AdultsRethinking Blood Pressure ReadingsPsoriasis Meds Might Help Fight Heart Trouble, TooSurgery Restores Movement to Kids With Polio-Like IllnessYou've Fainted. How Long Do You Need to Stay in the ER?Could Germs in Your Gut Send You Into Depression?Health Tip: Prevent the Spread of Head LiceExercise Your Right to Fight DiseaseObesity-Linked Cancers On the Rise Among Young AmericansUnraveling the Mystery of HiccupsAHA: 7 Things That Can Affect the Heart -- And What to Do About ThemStatins Help the Heart, No Matter What Your AgeFirst Generic Version of Advair Diskus Approved for Asthma, COPDMore Smoking, Heart Woes Boost Native Americans' Stroke RiskNearly Half of American Adults Have Unhealthy Hearts: ReportHealth Tip: Avoid Winter Skin RashesHow to Prevent and Treat Eye AllergiesPolar Vortex Brings Frostbite Danger: Protect YourselfAHA: Could a Heart Attack or Stroke Lead to Early Menopause?
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

First Drug Approved for Rare Eye Disease

HealthDay News
by -- Scott Roberts
Updated: Aug 23rd 2018

THURSDAY, Aug. 23, 2018 (HealthDay News) -- Oxervate (cenegermin) has been approved by the U.S. Food and Drug Administration to treat neurotrophic keratitis, a rare disease of the eye's cornea.

The cornea is the clear layer that covers the colored portion at the front of the eye.

Neurotrophic keratitis affects fewer than five in 10,000 people, the FDA said. The disease, causing loss of corneal sensation, leads to damage of this vital part of the eye.

"While the prevalence of neurotrophic keratitis is low, the impact of this serious condition on an individual patient can be devastating," Dr. Wiley Chambers, an ophthalmologist in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

Oxervate, produced as an eyedrop, was evaluated in a clinical study involving 151 people with neurotrophic keratitis. Some participants were given Oxervate, while others were given a placebo eye drop. Complete corneal healing was reported among 70 percent of people treated with Oxervate, compared with 28 percent of those given the placebo, the FDA said.

The most common side effects of the drug included eye pain, enlarged blood vessels in the eye, eye inflammation and watery eyes.

Oxervate is produced by the Italian firm Dompé farmaceutici.

More information

Visit the FDA to learn more.